1

SUPPORTING INFORMATION

2

3 MATERIALS AND METHODS

Cell culture. Primary normal human bronchial epithelial cells (NHBE, Lonza) from genetically 4 5 independent donors were grown as monolayers from low passages in serum-free pre-defined bronchial epithelial cell growth medium according to manufacturer's instructions (BEGM 6 7 BulletKit, Lonza). NHBEs were treated in 12-well plates at 80% confluence. To avoid effects 8 induced by growth factors in the BEGM medium, cells were rested in basal medium without 9 supplements for 12 hours, then stimulated with icatibant at 1 nM or hydrocortisone at 10 µM, followed by further 24 hours of infection with SARS-CoV-2 at the biosafety level 3 laboratory. 10 11 For RNA analysis, cells were lysed in RLT buffer (Qiagen, Hilden, Germany). For protein 12 analysis, cells were lysed in 1x protein extraction buffer provided with the ACE2 ELISA Kit 13 (Abcam, Cambridge, UK). Cell culture supernatant was collected for further viral and cytolytic 14 analysis.

15

16 Infection with SARS-CoV-2. The SARS-CoV-2 isolate hCoV-19/Germany/BAV-PL-17 virotum-nacq/2020 (GISAID accession ID: EPI ISL 582134) was derived from patient 18 material and amplified on Vero E6 cells (passage 0; ATCC, Manassas, US) and used for 19 infection experiments (passage 4) with an MOI of 0.5 (determined by plaque assay) by adding 20 virus stock to the BEBM culture medium after 24 hours of stimulation. Time of harvest after 21 inoculation was dependent on the experimental setting. For repetitive treatment with icatibant 22 of NHBEs post-infection (Fig.2D-I), NHBEs from 8 genetically independent donors were 23 infected with SARS-CoV-2 with a MOI of 0.5 at T-6 and after 6 hours (T0), treatment with a 24 range of doses of icatibant was started and repeated every 24 hours. Cells were harvested at 24, 25 48, 72 and 96 hours after treatment start and subjected to RNA extraction and relative viral 26 RNA quantification normalized to a housekeeper index.

27

28	Plaque assay. Supernatant of SARS-CoV-2-infected NHBEs was titrated (1:5 dilutions of the
29	stock) in Dulbecco's Modified Eagle Medium (DMEM) with 1% penicillin / streptomycin, 1%
30	L-glutamine, 1% non-essential aminoacids, and 1% sodium pyruvate (all Gibco, Thermo Fisher
31	Scientific, Carlsbad, CA, USA) in a total volume/well of 100 µl on 96-well plates containing
32	70-80 % confluent Vero E6 cells. After 2 hours, the inoculum was discarded, and cells were
33	layered with 100 μ l MEM containing 0.5 % carboxymethyl cellulose (1,500 cP, Sigma-Aldrich,
34	St. Louis US). 48 hours post inoculation, 100 µl formaldehyde was added to a final
35	concentration of 5 % for 15 min. Supernatant was taken off, cells were washed with PBS twice
36	and incubated with crystal violet (Sigma-Aldrich) solution for 15 min and washed with PBS
37	again. Plaque-forming units per milliliter pfu/ml were calculated with the formula pfu/mL =
38	number of plaques/dilution x volume of analyzed supernatant.

39

40 RNA isolation and gene expression analysis. mRNA was extracted from patient nasal 41 brushings and from NHBEs using RNeasy Micro Kit (Qiagen) with on-column DNase digestion 42 (Qiagen). RNA quantification and quality assessment were performed using Nanodrop 43 Technologies (Wilmington) and RNA 6000 Nano Chip Kit with the Agilent 2100 Bioanalyzer 44 (Agilent Technologies, Waldbronn, Germany) according to manufacturer's instructions.

45

46 RT-qPCR-based detection of SARS-CoV-2 RNA. Isolated RNA was subject to cDNA 47 synthesis by SuperScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen). On a 48 LightCycler 480 II (Roche Diagnostics, Penzberg, Germany) total SARS-CoV-2 RNA was 49 quantified using SARS-CoV-2 N1 primers and probe according to CDC guidelines and a SYBR 50 Green PCR mix (Roche Diagnostics). SARS-CoV-2 genomic RNA was quantified using RdRP 51 primers. The specific primers used in real-time PCR are listed in Table S21. SARS-CoV-2 RNA 52 was normalized with relative quantification to endogenous control ACTB using the 1/ECT 53 formula.

54

55 **3D-bronchial air-liquid interphase organoid cultures.** Low passage primary NHBEs were expanded to 95% confluence in PneumaCult-Ex Plus expansion medium (Stemcell) according 56 57 to manufacturer's instructions. Corning transwell polyester membrane cell culture inserts (type 58 3460, Merck) were precoated with 1% collagen (Sigma-Aldrich) and the cells were transferred 59 to 12-well plates containing precoated transwell inserts on day 0 with a density of 3×10^5 60 cells/cm². Every other day, PneumaCult-Ex Plus expansion medium (Stemcell) was replenished 61 in apical and basal chambers. On day 3, cells were lifted to air (air-lift) by removing the apical medium. Medium in the basal chamber was exchanged for Pneumacult-ALI maintenance 62 63 medium (Stemcell). Excess mucus was removed from day 7. Once a week, the transepithelial 64 electrical resistance (TEER) was measured using an EVOM2 instrument (World Precision 65 Instruments). With a TEER of >700, but from day 21 at the earliest, the 3D organoid cultures were regarded as completely differentiated and were then treated and infected with SARS-CoV-66 67 2.

68

69 Infection of 3D organoid cultures.

70 24 hours prior to treatment of the 3D air-liquid interphase organoid cultures, the supplement 71 hydrocortisone was withdrawn. The cultures were then pretreated from the basal side 72 with/without 1 nM icatibant (HOE 140 (icatibant), Sigma-Aldrich) for 24 hours. Subsequently, 73 SARS-CoV-2 viral suspension (MOI 0.5, strain hCoV-19/Germany/BAV-PL-virotum-74 nacq/2020) was added from the apical side and incubated for 2 hours, then the virus suspension 75 was removed with PBS washes and the cultures were kept for another 46 hours before harvest. 76

FFPE sections of 3D organoid cultures. Cultures were fixed in 4% paraformaldehyde and
embedded in paraffin and sections of 4 µm thickness were produced at the routine diagnostics

at the Medical School of the Technical University of Munich, Campus Biederstein. Slides were
subjected to standard hematoxylin eosin staining to identify the culture structure by light
microscopy.

82

83 Tissue homogenization and murine ACE2 ELISA. Tissue lysates were prepared by 84 homogenization in ice-cold lysis buffer (Cell Signaling) to a final concentration of 2x lysis 85 buffer in water, containing protease inhibitor (Complete Mini, Roche). 0.1 ml of lysis buffer 86 was added per 100 mg of tissue. Tissue was homogenized using metal beads and Qiagen tissue 87 lyser 20/s for 90 seconds until it was completely homogenized. Samples were centrifuged for 10 minutes at 11,000 x g at 4°C and supernatants were transferred to fresh tubes. Total protein 88 89 concentration was determined with the Pierce BCA Protein Assay Kit (Thermo Scientific) to 90 determine extraction efficacy across samples, before further analysis by ELISA. Mouse ACE2 91 ELISA (PicoKine Kit, Boster Bio) was performed according to the manufacturer's instructions 92 using tissue lysate diluted 1:100. Colorimetric readout was acquired using Spark microplate 93 reader (Tecan). Data analysis was performed using Microsoft Excel, R and GraphPad Prism.

94

95 Reverse transcription and quantitative real-time gPCR. Isolated total RNA was reverse 96 transcribed using a high-capacity cDNA kit (Applied Biosystems) according to manufacturer's 97 instructions. Real-time PCR profiles were visualized using FastStart Universal SYBR Green 98 Mastermix (Roche) and quantified by the ViiA 7 Real-Time PCR System (Applied 99 Biosystems). The specific primers used in real-time PCR are listed in supplementary Table S21. 100 ACE2 and TMPRSS2 mRNA expression was normalized to housekeeping gene index ACTB 101 and *HPRT* and the relative quantification was performed using the comparative threshold cycle 102 $(2^{-\Delta\Delta Ct})$ method (relative gene expression). All amplifications were carried out at least in 103 duplicate.

104

105 Gene expression analysis using Agilent microarray technologies. Microarray experiments 106 were performed using MIAME criteria. Genespring Software GX 14.9.1 (Agilent 107 Technologies) with minimal data reduction constraints (1.5-fold change and P<0.05 cutoff) was 108 used to analyze microarray data as previously described.^{1,2} Upon data import a standard 109 baseline transformation to the median of all values was performed, including log transformation 110 and computation of fold changes $(\log_2(A/B) = \log_2(A) - \log_2(B))$. Subsequently, a principle 111 component analysis was conducted, which revealed a homogenous component distribution. 112 Compromised array signals were excluded from further analysis (array spot is non-uniform if 113 pixel noise of feature exceeds threshold or is above saturation threshold). Genes with an 114 absolute log2 fold change larger than 1.5 and a p-value smaller than the testing level of 0.05 by 115 using the Moderated T-Test were defined as significantly differentially expressed hits. The 116 significantly regulated genes were summarized in entity lists (see supplemental tables). These 117 entity lists were analyzed for overlaps using Venn diagrams. Manhattan cityblock on entities 118 (Ward's linkage) was used to cluster changes in gene expression.

119 Gene Ontology (GO) terms "0007267", "0005125", "0008009", and "0005615" for secreted 120 factors, GO terms "0007267", "0005125", "0008009", and "0005615" for identification of biomarkers, GO terms "0038023", "0004896", "0004888", and "0005887" for surface receptors, 121 122 GO terms "0009615", "0039528", "0039530", "0039639", "0051607", and "0009597" for anti-123 viral response. Membrane-bound cell surface receptors were selected from a Venn diagram 124 analysis of the GO-term selection of surface receptors (see above) minus the GO-term selection 125 of secreted genes (see above) in order to isolate surface receptors that are not as well secreted 126 as soluble ligands. The data discussed in this publication will be deposited in NCBI's Gene 127 Expression Omnibus and are accessible through GEO Series accession number pending.

128

129 String network analysis. Protein-protein interactions were computed using an open-access 130 tool, the string network analysis version 11.0 (string-db.org)³⁻¹³ in order to extract enriched 131 cellular processes and pathways affected by icatibant treatment. The classical classification 132 systems Gene Ontology was relevant for this study. Enriched entities are colored in the 133 interaction plots: violet for GO:0007186 "G protein-coupled receptor signaling pathway" and 134 light green for GO:0006811 "Ion transport" in Figure 2.

135

Cytotoxicity assay. Lactate Dehydrogenase Assay (LDH) assay for assessing the cytotoxicity
of virus-infected NHBES in combination with or without icatibant was performed using the
LDH-detecting CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega GmbH)
according to manufacturer's instructions.

140

141 ELISA for human ACE2 levels. Protein levels of ACE2 in NHBE cell lysates were determined
142 using the human ACE2 ELISA Kit (Abcam). Assays were performed according to
143 manufacturer's instructions.

144

145 Statistical analysis. Two-tailed Mann-Whitney U tests were used to determine statistical 146 significance (GraphPad Prism Version 8.4.2, GraphPad Software). For the in vivo mouse study, 147 we performed a prospective power analysis based on human data that predict a 33% reduction 148 in ACE2 following icatibant treatment (mean 1: 1; mean 2: 0.666; SD: 0.26; alpha = 0.05; P =149 0.9, power.t.test in R, rounded up). In accordance with the criteria of this a priori power 150 analysis, we used a 1-tailed t-test, that compared icatibant-treated groups with untreated groups, 151 resulting in 12 animals per group. Here, we have specifically tested the hypothesis for a 152 downregulation of ACE2 only in mice treated with icatibant compared to untreated mice. The 153 half maximal inhibitory concentration (IC₅₀) values were deferred from sigmoidal interpolation 154 of a standard curve using a robust nonlinear regression model in GraphPad Prism. Results are 155 depicted as median with range, if not otherwise indicated in the figure legends. P<0.05 was 156 considered statistically significant. Statistically significant differences were depicted as p157 values *P<0.05, **P<0.01, and ***P<0.001.

158

- 159 Data availability statement. The data discussed in this publication are deposited in NCBI's
- 160 Gene Expression Omnibus and are accessible under the GEO Series accession number
- 161 GSE176405.

162

163 SUPPLEMENTAL TABLES

- 164 Table S1. DEGs from transcriptome analysis filtered on secreted factors from nasal scrapings
- 165 from SARS-CoV-2 acute positive patients compared to negative patients
- 166 Table S2. DEGs from transcriptome analysis filtered on kallikreins from nasal scrapings from
- 167 SARS-CoV-2 acute positive patients compared to negative patients
- 168 Table S3. DEGs from transcriptome analysis filtered on kinin-kallikrein-system members from
- 169 nasal scrapings from SARS-CoV-2 acute positive patients compared to negative patients
- 170 Table S4. DEGs comparing SARS-CoV-2 + B2R antagonist versus SARS-CoV-2
- 171 Table S5. DEGs comparing SARS-CoV-2 + hydrocortisone (HC) versus SARS-CoV-2
- 172 Table S6. DEGs of antiviral epithelial response comparing SARS-CoV-2 versus medium
- 173 Table S7. DEGs of antiviral epithelial response comparing SARS-CoV-2 versus medium
- 174 Table S8. Gene expression of members of the acute-phase response comparing SARS-CoV-2
- 175 versus medium
- Table S9. Gene expression of members of RAS and KKS comparing SARS-CoV-2 versusmedium
- 178 Table S10. Differentially expressed interleukins comparing SARS-CoV-2 versus medium
- 179 Table S11. Potential viral entry receptor DEGs comparing SARS-CoV-2 versus medium
- 180 Table S12. Toll-like receptor (TLR) DEGs comparing SARS-CoV-2 versus medium
- 181 Table S13. Chemokine DEGs comparing SARS-CoV-2 versus medium
- Table S14. Gene expression of potential viral entry receptors comparing SARS-CoV-2 versusmedium
- Table S15. Membrane-bound receptor DEGs comparing SARS-CoV-2 + B2R antagonist versus
 SARS-CoV-2
- 186Table S16. Membrane-bound receptor DEGs comparing SARS-CoV-2 + B2R antagonist versus
- 187 SARS-CoV-2 ($P \le 0.05$; FC >=2.5)

- 188 Table S17. Interactions output of String network analysis of membrane-bound receptor DEGs
- 189 comparing SARS-CoV-2 + B2R antagonist versus SARS-CoV-2
- 190 Table S18. Cellular process enrichment analysis output of String network analysis of
- 191 membrane-bound receptor DEGs comparing SARS-CoV-2 + B2R antagonist versus SARS-
- 192 CoV-2
- Table S19. Membrane-bound cell surface receptor DEGs, upregulated in SARS-CoV-2 versusmedium
- 195 Table S20. Cut set: Membrane-bound cell surface receptor DEGs, upregulated in SARS-CoV-
- 196 2 versus medium and downregulated in SARS-CoV-2 + B2R antagonist versus SARS-CoV-2
- 197 Table S21. Reagents
- 198

199 SUPPLEMENTAL FIGURE LEGENDS

200 Figure S1. Epithelial response of primary NHBEs to SARS-CoV-2 infection.

201 Gene expression analysis of NHBEs after 24 hours of SARS-CoV-2 infection versus medium 202 using microarray technology: A) Heat map of selected genes of the KKS and RAS are depicted 203 independent of significance analysis. All entities are shown. Asterisks indicate significantly 204 regulated genes (P<0.05) in SARS-CoV-2 compared to medium. Heat map of gene expression 205 analysis of B) epithelium-derived interleukins, C) a selection of confirmed and potential SARS-206 CoV-2 entry receptors, D) Toll-like family members, E) factors involved in the immediate 207 antiviral response of infected epithelial cells, and of E) chemokines. In B-F, only significantly 208 regulated entities in SARS-CoV-2-infected versus uninfected NHBEs are shown. Color code 209 indicates Log2-fold change from low (blue) through 0 (white) to high (red). Duplicate gene 210 names indicate the abundance of two or more isoforms of the same gene in the analysis.

211

Figure S2.

213	A) Analysis of <i>TMPRSS2</i> gene expression by qPCR after 24 hours of pre-treatment of NHBEs
214	of 10 donors with/without 1 nM B2R antagonist, followed by SARS-CoV-2 inoculation for 24
215	hours of NHBEs. Results are depicted as median with range. B) ACE2 gene expression analysis
216	using qPCR after 24 hours of pre-treatment with/without 10 μ M hydrocortisone (HC) followed
217	by 24 hours of SARS-CoV-2 infection of NHBEs. Results are depicted as median with range.
218	For Figures S2A and B, statistical tests compared SARS-CoV-2-infected versus uninfected
219	samples or B ₂ R antagonist-treated versus untreated samples. C) Heat map of gene expression
220	analysis of membrane-bound cell surface receptors included in pathway analysis in Figures
221	4A,B, the were the highest downregulated upon pre-treatment with B ₂ R antagonist during
222	SARS-CoV-2 infection of NHBES are depicted. SARS-CoV-2 + B ₂ R antagonist and SARS-
223	CoV-2 are shown (FC≥2.5; P≤0.05). Color code indicates Log2-fold change from low (blue)
224	through 0 (white) to high (red). Duplicate gene names indicate the abundance of two or more
225	isoforms of the same gene in the analysis.

228 SUPPLEMENTARY REFERENCES

- Zissler UM, Chaker AM, Effner R, et al. Interleukin-4 and interferon-gamma orchestrate an epithelial polarization in the airways. *Mucosal Immunol.* 2016;9(4):917-926.
- Zissler UM, Jakwerth CA, Guerth FM, et al. Early IL-10 producing B-cells and coinciding Th/Tr17 shifts during three year grass-pollen AIT. *EBioMedicine*. 2018;36:475-488.
- 3. Franceschini A, Lin J, von Mering C, Jensen LJ. SVD-phy: improved prediction of
 protein functional associations through singular value decomposition of phylogenetic
 profiles. *Bioinformatics*. 2016;32(7):1085-1087.
- 4. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res.*240 2013;41(Database issue):D808-815.
- 5. Jensen LJ, Kuhn M, Stark M, et al. STRING 8--a global view on proteins and their
 functional interactions in 630 organisms. *Nucleic Acids Res.* 2009;37(Database
 issue):D412-416.
- Snel B, Lehmann G, Bork P, Huynen MA. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. *Nucleic Acids Res.* 2000;28(18):3442-3444.
- 247 7. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional 248 interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res.* 249 2011;39(Database issue):D561-568.
- 8. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res.* 2015;43(Database issue):D447-452.
- 9. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019;47(D1):D607-D613.
- Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res.* 2017;45(D1):D362-D368.
- von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database
 of predicted functional associations between proteins. *Nucleic Acids Res.*2003;31(1):258-261.
- von Mering C, Jensen LJ, Kuhn M, et al. STRING 7--recent developments in the
 integration and prediction of protein interactions. *Nucleic Acids Res.* 2007;35(Database
 issue):D358-362.
- von Mering C, Jensen LJ, Snel B, et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. *Nucleic Acids Res.*267 2005;33(Database issue):D433-437.
- 268